Literature DB >> 15861213

Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.

Liang Cheng1, Timothy D Jones, Chong-Xian Pan, Ayana Barbarin, John N Eble, Michael O Koch.   

Abstract

Some investigators consider small-volume prostate cancer (0.5 ml or less) without Gleason pattern 4/5 elements as clinically insignificant. The objective of this study was to characterize the anatomic distribution and pathologic features of small tumors (aggregate volume of 0.5 ml or less) in whole-mount prostatectomy specimens. Between 1999 and 2003, 371 consecutive patients underwent radical prostatectomy at the Indiana University Hospitals for localized prostate cancer. Patients who received hormonal or radiation therapy prior to the surgery were excluded from the study. A total of 62 specimens with total tumor volume of 0.5 ml or less were identified and included in this study. All specimens were embedded and whole-mounted. Tumor volume was measured using the grid method. The mean age at the time of surgery was 59 years (median, 61 years; range, 37-72 years). The mean preoperative prostate-specific antigen (PSA) was 6.5 ng/ml (range: 0.3-18 ng/ml). The mean prostate weight was 53 g (range: 16-132 g). The mean tumor volume was 0.29 ml (median, 0.35 ml; range, 0.02-0.48 ml). Tumor multifocality and bilaterality were present in 69 and 37% of cases, respectively. Three (5%) had positive surgical margins. The largest tumor was located in the peripheral zone, transitional zone, and central zone in 79, 16, and 5% of cases, respectively. The largest tumor was located in the anterior prostate in 10 cases (16%) and in the posterior prostate in 52 cases (84%). The distribution of Gleason scores was 5 (12 cases, 19 %), 6 (40 cases, 65 %), and 7 (10 cases, 16 %). One case had a primary Gleason pattern 4. None had extraprostatic extension, seminal vesicle invasion, or lymph node metastasis. Small-volume prostate cancers are often multifocal and bilateral, with predilection for the peripheral zone. Of these small-volume cases, 16% had Gleason pattern 4 and might, therefore, be clinically significant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861213     DOI: 10.1038/modpathol.3800431

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.

Authors:  Safwan Escaff; Jesús M Fernández; Luis O González; Aurelio Suárez; Salomé González-Reyes; José M González; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

Review 2.  Selection and mutation in the "new" genetics: an emerging hypothesis.

Authors:  Bruce Gottlieb; Lenore K Beitel; Carlos Alvarado; Mark A Trifiro
Journal:  Hum Genet       Date:  2010-01-23       Impact factor: 4.132

3.  There is no role for focal therapy in prostate cancer.

Authors:  Peter Black
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

Review 4.  MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results.

Authors:  Christiaan G Overduin; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

5.  Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer.

Authors:  Cheng Cheng Huang; Fang-Ming Deng; Max X Kong; Qinhu Ren; Jonathan Melamed; Ming Zhou
Journal:  Virchows Arch       Date:  2014-03-12       Impact factor: 4.064

6.  Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era.

Authors:  Herbert Augustin; Marco Auprich; Philipp Stummvoll; Katja Lipsky; Karl Pummer; Peter Petritsch
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

7.  Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer.

Authors:  Amit L Jain; Abhinav Sidana; Mahir Maruf; Dordaneh Sugano; Brian Calio; Bradford J Wood; Peter A Pinto
Journal:  Urol Oncol       Date:  2018-12-03       Impact factor: 3.498

8.  Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy.

Authors:  Sandeep Sankineni; Arvin K George; Anna M Brown; Soroush Rais-Bahrami; Bradford J Wood; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Abdom Imaging       Date:  2015-10

Review 9.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

10.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.